Filing Flows

Filing Flows › Companies › Myriad Genetics › Cash flow

Myriad Genetics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.5M in Q3 2026 · −$19.9M over twelve months

Operating cash flow−$6.5M
Free cash flow−$6.5M
Cash conversion cycle50 days

Analysis

In Q3 2026, Myriad Genetics generated −$6.5M of operating cash flow. That is $27.6M less than in Q3 2025 ($21.1M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$19.9M; the largest uses were operating cash flow ($19.9M), other investing ($17.8M), other financing ($8.0M); besides operations, cash came from shares issued ($3.4M); the cash balance fell by $47.0M.

Operating cash flow was −$6.5M against net income of −$43.9M. The largest differences: depreciation & amortization +$12.6M, stock-based pay +$9.2M, accrued liabilities +$7.2M.

Its cash conversion cycle was 50 days (receivables 49 + inventory 42 − payables 41).

Free cash flow

Myriad Genetics: free cash flow by quarterMyriad Genetics: free cash flow by quarter$6.6MQ4 2024−$16.3MQ1 2025−$13.6MQ2 2025$21.1MQ3 2025$10.6MQ4 2025−$15.7MQ1 2026−$8.3MQ2 2026−$6.5MQ3 2026
Operating cash flow less capital spending.
Myriad Genetics: operating cash flow against capital spendingMyriad Genetics: operating cash flow against capital spendingOperating cash flowCapital spending$6.6M$0Q4 2024−$16.3M$0Q1 2025−$13.6M$0Q2 2025$21.1M$0Q3 2025$10.6M$0Q4 2025−$15.7M$0Q1 2026−$8.3M$0Q2 2026−$6.5M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$6.5M, Capital spending $0.

Capital allocation, year by year

Myriad Genetics: where the cash came from (up) and went (down), by fiscal yearMyriad Genetics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow $18.6MFY2021: Net borrowing −$226MFY2021: Shares issued $91.8MFY2021: Asset sales $379MFY2021: Capital spending −$18.0M$490MFY2021FY2022: Operating cash flow −$106MFY2022: Shares issued $6.3MFY2022: Capital spending −$45.3MFY2022: Acquisitions −$57.2M$6.3MFY2022FY2023: Operating cash flow −$111MFY2023: Net borrowing $39.8MFY2023: Shares issued $124M$163MFY2023FY2024: Operating cash flow −$8.7MFY2024: Net borrowing $100KFY2024: Shares issued $5.9MFY2024: Asset sales $8.8M$14.8MFY2024FY2025: Operating cash flow $1.8MFY2025: Net borrowing $84.5MFY2025: Shares issued $3.3M$89.6MFY2025
Over these 5 years operating cash flow totalled −$206M; the largest uses were net borrowing ($226M) and operating cash flow ($226M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$107M
Debt$121M
Net debt$14.0M
Cash runway5.4 years

Myriad Genetics is burning cash: its operations consume cash, a free cash flow of −$19.9M a year at the current rate against $107M of cash and investments: a runway of about 5.4 years before any new financing.

Where the cash came from and went

Myriad Genetics: sources (+) and uses (−) of cash, Q3 2026Myriad Genetics: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$9.0MOperating cash flow−$6.5MOther investing−$2.1MTaxes on employees’ shares−$200KNet borrowing (+) / repaid (−)−$100KExchange rates−$100K
Myriad Genetics: sources (+) and uses (−) of cash, TTM to Q3 2026Myriad Genetics: sources (+) and uses (−) of cash, TTM to Q3 2026Cash drawn (+) / kept (−)$47.0MOperating cash flow−$19.9MOther investing−$17.8MOther financing−$8.0MTaxes on employees’ shares−$4.7MShares issued$3.4M

From profit to cash

Myriad Genetics: net income to operating cash flow, Q3 2026Myriad Genetics: net income to operating cash flow, Q3 2026Net income−$43.9MDepreciation & amortization$12.6MStock-based pay$9.2MReceivables$3.9MPayables−$1.3MAccrued liabilities$7.2MOperating cash flow−$6.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202649424150
Q2 202656424552
Q1 202654424551
Q4 202551454551
Q3 202557454755
Q2 202555424453
Q1 202555414452
Q4 202454414848

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$6.5M−$100K—$9.0M−$6.5M
Q2 2026−$8.3M−$200K—$9.2M−$8.3M
Q1 2026−$15.7M−$100K—$25.3M−$15.7M
Q4 2025$10.6M—$600K$3.5M$10.6M
Q3 2025$21.1M−$60.1M—−$71.1M$21.1M
Q2 2025−$13.6M−$100K—$17.3M−$13.6M
Q1 2025−$16.3M$19.4M—$10.9M−$16.3M
Q4 2024$6.6M$400K$2.9M−$2.1M$6.6M

Myriad Genetics: income statement and cash flow

Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%. The chart follows the revenue to costs, profit and cash.

Myriad Genetics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.